"
Team:HZAU-China/Human practice=2
From 2013.igem.org
(Difference between revisions)
| (14 intermediate revisions not shown) | |||
| Line 3: | Line 3: | ||
<style> | <style> | ||
#background{ | #background{ | ||
| - | background | + | background:url(https://static.igem.org/mediawiki/2013/8/80/Old_wall.jpg); |
| - | float: left; | + | float:left; |
| - | min- | + | min-heiht:600px; |
| - | width: | + | width: 1000px; |
} | } | ||
#sidebar { | #sidebar { | ||
| Line 13: | Line 13: | ||
float: left; | float: left; | ||
height: auto; | height: auto; | ||
| - | width: | + | width: 240px; |
| - | padding-top: | + | padding-top: 10px; |
| - | padding-left: | + | padding-left: 15px; |
} | } | ||
#paragraphs { | #paragraphs { | ||
| - | background-color: | + | background-color: transparent; |
float: right; | float: right; | ||
height: auto; | height: auto; | ||
| - | + | text-align: justify; | |
| - | + | padding-top: 10px; | |
| - | padding- | + | padding-right:15px; |
| - | + | ||
width: 710px; | width: 710px; | ||
} | } | ||
| Line 32: | Line 31: | ||
} | } | ||
</style> | </style> | ||
| - | |||
| - | |||
| - | |||
<style> | <style> | ||
*{margin:0px;padding:0px;} | *{margin:0px;padding:0px;} | ||
| Line 41: | Line 37: | ||
ul.menu:after{content:"";display:block;height:0;clear:both;visibility:hidden;} | ul.menu:after{content:"";display:block;height:0;clear:both;visibility:hidden;} | ||
ul.menu, | ul.menu, | ||
| - | ul.menu ul {padding:0;margin:0;list-style:none;position:;width: | + | ul.menu ul {padding:0;margin:0;list-style:none;position:;width:220px;background:#d3f18c;font-family:arial, sans-serif;} |
| - | ul.menu {z-index:100;padding:10px;margin:0 auto | + | ul.menu {z-index:100;padding:10px;margin:0 auto;} |
ul.menu ul {z-index:50; | ul.menu ul {z-index:50; | ||
-webkit-transition: 0.5s; | -webkit-transition: 0.5s; | ||
| Line 50: | Line 46: | ||
transition: 0.5s; | transition: 0.5s; | ||
} | } | ||
| - | ul.menu li {line-height:30px;position:relative | + | ul.menu li {line-height:30px;position:relative;} |
ul.menu > li {margin-top:2px;font-size:12px;} | ul.menu > li {margin-top:2px;font-size:12px;} | ||
ul.menu > li a {font:normal 16px/29px arial, sans-serif;color:#fff;text-decoration:none;} | ul.menu > li a {font:normal 16px/29px arial, sans-serif;color:#fff;text-decoration:none;} | ||
| - | ul.menu label.open {display:block;background:# | + | ul.menu label.open {display:block;background:#517b1f no-repeat 170px 12px;line-height:30px;position:relative;z- |
| - | + | ||
index:100;font:normal 12px/30px arial, sans-serif;color:#fff;border-radius:10px 10px 0 0;} | index:100;font:normal 12px/30px arial, sans-serif;color:#fff;border-radius:10px 10px 0 0;} | ||
| - | + | ul.menu span {display:block;background:#517b1f;line-height:30px;position:relative;z-index:100;font-size: 16px;padding-left:10px;} | |
| - | ul.menu span {display:block;background:# | + | |
ul.menu label img {position:absolute;left:0;top:0;width:100%;height:30px;} | ul.menu label img {position:absolute;left:0;top:0;width:100%;height:30px;} | ||
ul.menu ul li {margin-top:-30px; | ul.menu ul li {margin-top:-30px; | ||
| Line 66: | Line 60: | ||
transition: 0.5s; | transition: 0.5s; | ||
} | } | ||
| - | ul.menu ul li a {display:block;font:normal 16px/29px arial, sans-serif;color:#000;background:# | + | ul.menu ul li a {display:block;font:normal 16px/29px arial, sans-serif;color:#000;background:#b3e24b;} |
| - | ul.menu ul li a:hover {background:# | + | ul.menu ul li a:hover {background:#d3f18c;} |
ul.menu input {position:absolute;left:-9999px;} | ul.menu input {position:absolute;left:-9999px;} | ||
ul.menu li input:checked + label {background:#069;} | ul.menu li input:checked + label {background:#069;} | ||
| - | ul.menu li input:checked ~ ul {background:# | + | ul.menu li input:checked ~ ul {background:#b3e24b;padding-bottom:10px;} |
ul.menu li input:checked ~ ul li {margin-top:0;} | ul.menu li input:checked ~ ul li {margin-top:0;} | ||
ul.menu label.close {display:block;width:200px;height:30px;background:transparent url("/jscss/demoimg/201208/u-arrow.gif") | ul.menu label.close {display:block;width:200px;height:30px;background:transparent url("/jscss/demoimg/201208/u-arrow.gif") | ||
| Line 80: | Line 74: | ||
ul.menu input.close:checked ~ ul li {margin-top:-30px;} | ul.menu input.close:checked ~ ul li {margin-top:-30px;} | ||
</style> | </style> | ||
| - | + | ||
| - | <script | + | |
| + | <script> | ||
$(document).ready(function(){ | $(document).ready(function(){ | ||
var topMain=$("#sidebar").height()+100//是头部的高度加头部与nav导航之间的距离 | var topMain=$("#sidebar").height()+100//是头部的高度加头部与nav导航之间的距离 | ||
| Line 96: | Line 91: | ||
<body> | <body> | ||
| - | <ul class="menu"> | + | <div id="background"> |
| - | <li><a href=" | + | <div id="sidebar"> |
| - | <li><a href="https://2013.igem.org/Team:HZAU-China/Human_practice=2"><span span style="font-size: | + | <body> |
| - | <li><a href=" | + | <ul class="menu"> |
| - | <li><a href=" | + | <li><a href="https://2013.igem.org/Team:HZAU-China/Human_practice=1"><span>Meeting with WHU and HUST</span></a></li> |
| - | </body> | + | <li><a href="https://2013.igem.org/Team:HZAU-China/Collaboration"><span>Collaboration</span></a></li> |
| + | <li><a href="https://2013.igem.org/Team:HZAU-China/Human_practice=2"><span span style="font-size:20px;color=#fff;">Visiting Keqian Biotech Company</span></a></li> | ||
| + | <li><a href="https://2013.igem.org/Team:HZAU-China/Human_practice=3"><span>Making IGEM and Synthetic Biology Popular</span></a></li> | ||
| + | <li><a href="https://2013.igem.org/Team:HZAU-China/Human_practice=4"><span>Understanding the Safety assessment of GM rice</span></a></li> | ||
| + | <li><a href="https://static.igem.org/mediawiki/2013/1/11/IGEM%E7%89%B9%E5%88%8A.pdf"><span>Publication</span></a></li> | ||
| + | </body> | ||
| + | </div> | ||
| + | <div id="paragraphs"> | ||
| + | <p><br></p> | ||
| + | <center> | ||
| + | <span style="font-size:40px;font-family:Cambria;margin-top:10px;line-height:80%">A Visit To Keqian Biotech Company</span> | ||
| + | </center> | ||
| + | <p><br></p> | ||
| - | + | <p style="font-size:16px;font-family:arial, sans-serif;">On a breezing sunny day, we paid a visit to Keqian Biotech Company. A manager greeted us, first of all, he led us to a small house, where we can see the whole process of how workers do their jobs in the GMP (abbreviation of Good Manufacturing Practice) workshop through the video monitoring. Then, we were taken to the lobby to have a look at the layout of the entire workshop, alongside the manager’s introductions to the principles of interior design and operational requirements. Finally, he gave us some answers about vaccine.</p> | |
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | + | ||
| - | <p style="font-size:16px;font-family:arial, sans-serif;">On a breezing sunny day,we | + | |
| - | <p style="text-align:center;"><a><img src="https://static.igem.org/mediawiki/2013/b/ | + | <p style="text-align:center;"><a><img src="https://static.igem.org/mediawiki/2013/b/bf/A_Visit_To_Keqian_Biotech_Company2.jpg" style="width:710px;"></a> |
</br> | </br> | ||
</p> | </p> | ||
| - | <p style="font-size: | + | <p style="font-size:13px;font-family:arial, sans-serif;sans-serif;text-align:center;">We had a group photo in the front door.</p> |
| - | <p style="text-align:center;"><a ><img src="https://static.igem.org/mediawiki/2013/ | + | <p style="text-align:center;"><a ><img src="https://static.igem.org/mediawiki/2013/1/19/A_Visit_To_Keqian_Biotech_Company1.jpg" style="width:710px;"></a> |
</br> | </br> | ||
</p> | </p> | ||
| Line 128: | Line 124: | ||
<h3>The following is the main contents of our conversation:</h3> | <h3>The following is the main contents of our conversation:</h3> | ||
<h3>1.The process of creating a new vaccine</h3> | <h3>1.The process of creating a new vaccine</h3> | ||
| - | <p style="font-size: | + | <p style="font-size:16px;font-family:arial, sans-serif;">Generally it will take a long period of time to select a vaccine strains and finally make it approved to come into the market.</p> |
| - | + | ||
<h3>2.Safety evaluations of vaccine before marketing</h3> | <h3>2.Safety evaluations of vaccine before marketing</h3> | ||
| - | <p style="font-size:16px;font-family:arial, sans-serif;">Every company has its own standard,when a new vaccine came out,it must pass its own standard then tested by COFCC,when all the tests have been passed,then it’s fine for it to come into the market.</p> | + | <p style="font-size:16px;font-family:arial, sans-serif;">Every company has its own standard, when a new vaccine came out, it must pass its own standard then tested by COFCC, when all the tests have been passed, then it’s fine for it to come into the market.</p> |
<h3>3.Current vaccine market and its economic outlook</h3> | <h3>3.Current vaccine market and its economic outlook</h3> | ||
| - | <p style="font-size:16px;font-family:arial, sans-serif;">Right before you make a vaccine,you should know about the epidemiological situation and correctly estimate the benefits of it.There is no need to produce a a vaccine for a disease that has been almost eliminated.To produce a vaccine,we need a good strain to improve yield and quality,we need good technology of vaccine adjuvants.By the way,there is a huge marketing potential here in China.</p> | + | <p style="font-size:16px;font-family:arial, sans-serif;">Right before you make a vaccine, you should know about the epidemiological situation and correctly estimate the benefits of it. There is no need to produce a a vaccine for a disease that has been almost eliminated. To produce a vaccine, we need a good strain to improve yield and quality, we need good technology of vaccine adjuvants. By the way, there is a huge marketing potential here in China.</p> |
<h3>4.The research progress of oral vaccine and live vector vaccine</h3> | <h3>4.The research progress of oral vaccine and live vector vaccine</h3> | ||
| - | <p style="font-size:16px;font-family:arial, sans-serif;">A large proportion of vaccines today in the market are traditional vaccines.Considering its absorption effect and the relatively vast land,veterinary oral drugs are very rare in China.But live vector vaccine is something we should definitely try and develop.</p> | + | <p style="font-size:16px;font-family:arial, sans-serif;">A large proportion of vaccines today in the market are traditional vaccines. Considering its absorption effect and the relatively vast land, veterinary oral drugs are very rare in China. But live vector vaccine is something we should definitely try and develop.</p> |
<br> | <br> | ||
| - | <p style="font-size:16px;font-family:arial, sans-serif;">Finally,special thanks to the welcoming manager,and thanks to Keqian Biotech Company!</p> | + | <p style="font-size:16px;font-family:arial, sans-serif;">Finally, special thanks to the welcoming manager, and thanks to Keqian Biotech Company!</p> |
</div> | </div> | ||
| Line 148: | Line 143: | ||
{{:Team：HZAU-China/background-footer}} | {{:Team：HZAU-China/background-footer}} | ||
| - | |||
Latest revision as of 02:51, 28 September 2013
On a breezing sunny day, we paid a visit to Keqian Biotech Company. A manager greeted us, first of all, he led us to a small house, where we can see the whole process of how workers do their jobs in the GMP (abbreviation of Good Manufacturing Practice) workshop through the video monitoring. Then, we were taken to the lobby to have a look at the layout of the entire workshop, alongside the manager’s introductions to the principles of interior design and operational requirements. Finally, he gave us some answers about vaccine.
We had a group photo in the front door.
The manager gave us a description of the whole layout of the workshop by design drawing in the labby.
The following is the main contents of our conversation:
1.The process of creating a new vaccine
Generally it will take a long period of time to select a vaccine strains and finally make it approved to come into the market.
2.Safety evaluations of vaccine before marketing
Every company has its own standard, when a new vaccine came out, it must pass its own standard then tested by COFCC, when all the tests have been passed, then it’s fine for it to come into the market.
3.Current vaccine market and its economic outlook
Right before you make a vaccine, you should know about the epidemiological situation and correctly estimate the benefits of it. There is no need to produce a a vaccine for a disease that has been almost eliminated. To produce a vaccine, we need a good strain to improve yield and quality, we need good technology of vaccine adjuvants. By the way, there is a huge marketing potential here in China.
4.The research progress of oral vaccine and live vector vaccine
A large proportion of vaccines today in the market are traditional vaccines. Considering its absorption effect and the relatively vast land, veterinary oral drugs are very rare in China. But live vector vaccine is something we should definitely try and develop.
Finally, special thanks to the welcoming manager, and thanks to Keqian Biotech Company!
